Zelira Therapeutics Limited (OTCMKTS:ZLDAF – Get Free Report) shares dropped 21.2% during trading on Monday. The company traded as low as $0.2050 and last traded at $0.2050. Approximately 114 shares traded hands during mid-day trading, a decline of 81% from the average session volume of 600 shares. The stock had previously closed at $0.26.
Zelira Therapeutics Price Performance
The stock’s fifty day simple moving average is $0.26 and its two-hundred day simple moving average is $0.32.
Zelira Therapeutics Company Profile
Zelira Therapeutics Limited is an Australia-based biopharmaceutical company focused on developing and commercializing cannabinoid-based medicines. The company’s activities include pharmaceutical research, product formulation, clinical development and the commercialization of medicinal cannabis products for conditions such as insomnia, chronic pain and other health disorders.
Zelira has developed proprietary cannabinoid formulations and has conducted clinical studies to evaluate their safety and potential therapeutic benefits.
Read More
- Five stocks we like better than Zelira Therapeutics
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Zelira Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zelira Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
